Daraxonrasib Phase 3 OS Doubling Sets New mPDAC Benchmark, But Resistance Threatens Durability

EMA Initiates Phased Review for Daraxonrasib in Metastatic Pancreatic Cancer

The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, a medicine intended for metastatic pancreatic cancer, to accelerate its assessment due to a high unmet medical need. This decision follows positive results from a Phase 3 study comparing daraxonrasib with chemotherapy in previously treated patients. Given the poor prognosis and limited options for these patients, daraxonrasib has been recognized as a high priority under EMA’s Cancer Medicines Pathfinder project, expediting its eligibility for a centralised marketing authorisation application. The phased review allows for data evaluation as it becomes available, potentially shortening the overall assessment timeline.

• Accelerated Assessment through Phased Review: The EMA's human medicines committee (CHMP) has commenced a phased review of daraxonrasib, a novel approach designed to expedite the assessment of medicines addressing high unmet medical needs. This process involves evaluating quality, nonclinical, and clinical data as it becomes available, prior to the submission of a complete marketing authorisation application, thereby shortening the overall review timeline compared to a standard evaluation.
• Addressing High Unmet Need in Metastatic Pancreatic Cancer: Daraxonrasib is being reviewed for metastatic pancreatic cancer, a condition characterized by very limited treatment options and a poor prognosis, with an average life expectancy of about six months for patients whose disease has progressed after prior treatment. The medicine's potential to address this critical unmet need led to its recognition as a high priority under EMA’s Cancer Medicines Pathfinder project and expedited eligibility for a centralised marketing authorisation.
• Basis in Phase 3 Data and Broader Regulatory Implications: The decision to initiate the phased review is based on results from a Phase 3 study that compared daraxonrasib with chemotherapy in previously treated metastatic pancreatic cancer patients. This review also serves as a precedent for provisions within the reformed EU pharmaceutical legislation, which aims to strengthen the use of phased reviews to enable more agile evaluations and earlier patient access to promising treatments.

Addressing the Critical Unmet Need in Metastatic Pancreatic Cancer

Metastatic pancreatic ductal adenocarcinoma (PDAC) remains one of oncology's most intractable challenges, with the disease projected to become the second leading cause of cancer-related death by 2030. Despite incremental advances in surgery, chemotherapy, and radiotherapy, five-year survival rates remain dismal — driven by late-stage diagnosis, rapid therapeutic resistance, and a near-absence of validated early detection tools. The field has increasingly coalesced around several high-priority unmet needs and underserved patient populations.

• Late-stage diagnosis and absence of early detection biomarkers: The majority of patients present with advanced, unresectable disease due to the asymptomatic nature of early-stage PDAC. General population screening is not feasible given low disease prevalence and the lack of validated specific biomarkers, creating an urgent need for cost-effective, targeted surveillance strategies and novel diagnostic modalities — including liquid biopsy approaches such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes.

• Therapeutic resistance as a driver of poor prognosis: Rapid emergence of resistance to cytotoxic and targeted therapies remains a central obstacle to improving survival outcomes. Resistance mechanisms include tumor cell plasticity, an immunosuppressive and fibrotic stromal microenvironment, and limited tumor penetration — all of which underscore the priority of identifying novel molecular targets and developing strategies to overcome treatment failure.

• Lack of biomarkers to guide treatment selection: Few validated biomarkers exist to stratify patients by likely chemotherapy benefit. Emerging candidates include E2F7 mRNA expression — identified as the most influential prognostic factor for postoperative overall survival (HR 1.386; 95% CI 1.005–1.912; p=0.045), with high expression correlating with reduced benefit from adjuvant S-1 — as well as histomorphology-based AI platforms capable of predicting differential benefit from fluoropyrimidine- versus gemcitabine-based regimens.

• High-risk populations requiring targeted surveillance: Patients with new-onset diabetes (NOD) represent a prioritized early detection cohort, given that Type 2 diabetes confers an approximately 2-fold increased PDAC risk, with the highest relative risk occurring within the first 2–3 years of diagnosis. Clinical triage strategies incorporating age ≥50–60 years, unintentional weight loss, rapid HbA1c escalation, and validated risk scores (e.g., ENDPAC) are being evaluated to identify candidates for imaging-based surveillance. Patients with premalignant lesions (e.g., intraductal papillary mucinous neoplasms), chronic pancreatitis, and a smoking history are also being actively targeted for risk stratification.

• Post-surgical recurrence in resected patients: Among patients undergoing curative resection, 72.2% experience recurrence, with 45.1% classified as early recurrence (within 12 months). Independent risk factors for early recurrence include age <60 years, lymph node metastasis, and absence of adjuvant chemotherapy — highlighting the need for refined patient stratification and adjuvant treatment optimization in the postoperative setting.

• Complex and underrepresented surgical populations: Standardized approaches and quality metrics are lacking for clinically challenging surgical subgroups, including patients who have received neoadjuvant therapy, frail or elderly patients, and those requiring vascular resection — populations that remain underrepresented in prospective trials and require dedicated evidence-generation efforts.

• Research infrastructure and precision oncology capabilities: Advancing biomarker discovery and treatment personalization requires collaborative consortia, integrated clinico-biological data ecosystems, and patient-derived 3D model platforms (organoids and spheroids). Machine learning and AI-driven analyses of molecular-genetic profiling data are increasingly employed to refine risk stratification and identify actionable targets across the PDAC patient continuum.

Daraxonrasib's Potential Impact on the mPC Treatment Landscape

The treatment landscape for metastatic pancreatic cancer (mPC) has advanced incrementally over the past five years, though the disease continues to carry a dismal prognosis, with 5-year survival rates remaining in the single digits (approximately 13%) and median survival under 12 months even with combination chemotherapy. FOLFIRINOX and nab-paclitaxel/gemcitabine have remained the cornerstone regimens, demonstrating modest survival benefits and improved resectability rates for borderline or locally advanced tumors. The CanStem111P phase 3 trial (NCT02993731), one of the largest mPC cohorts in a clinical trial setting, underscored the difficulty of improving upon this backbone: the addition of napabucasin — an investigational NQO1-bioactivated ROS generator — to nab-paclitaxel/gemcitabine yielded a median OS of 11.4 months versus 11.7 months for chemotherapy alone (HR 1.07; 95% CI 0.93–1.23), with no benefit observed even in the pSTAT3-positive biomarker-selected subgroup, and the trial was terminated for futility. More recently, a retrospective study from Taiwan evaluating the triplet regimen GAS (gemcitabine/nab-paclitaxel plus S-1) in 89 patients demonstrated a significantly higher ORR (48% vs. 18%, p=0.001), superior PFS (10.0 vs. 5.2 months, p=0.004), and improved OS (not reached vs. 8.5 months, p=0.016) compared with gemcitabine/nab-paclitaxel alone, consistent with the signal seen in the phase III NAPOLI-3 study supporting triplet chemotherapy.

Targeted and immunotherapy approaches have continued to face significant barriers in mPC, largely due to the tumor's immune-cold microenvironment, profound molecular heterogeneity, and the predominance of difficult-to-drug driver mutations. Molecular profiling studies conducted between 2017 and 2022 identified KRAS mutations in 87.9% of patients, with targetable alterations found in only 19.1% of KRAS-mutant patients compared with 33.3% of KRAS wild-type patients; critically, only 3.2% of patients receiving a Molecular Tumor Board-guided targeted therapy recommendation ultimately received such treatment. A meta-analysis of ten randomized controlled trials (n=2,444) evaluating erlotinib combined with chemotherapy found significant improvement in PFS (HR 0.78; 95% CI 0.66–0.92, p=0.003) but no meaningful OS benefit (HR 0.99; 95% CI 0.72–1.37, p=0.95), and the combination was associated with significantly higher rates of diarrhea and rash. Immunotherapy has similarly failed to demonstrate clinically meaningful benefit across the broader mPC population, with checkpoint inhibitors — transformative in other solid tumors — largely ineffective in this setting. A notable exception is an isolated case report of a patient with metastatic PDAC achieving a complete and durable metabolic response lasting 5.6 years following pembrolizumab administered post-chemoradiotherapy, though this remains anecdotal.

The most consequential recent development has been in KRAS-directed therapeutics, which are beginning to reshape the second-line treatment paradigm. The pan-RAS inhibitor daraxonrasib demonstrated an unprecedented doubling of overall survival compared with chemotherapy in a phase III trial for previously treated metastatic PDAC, positioning it as a potential new standard of care in the second-line setting. Complementing this, a phase 1 study of setidegrasib (ASP3082), a first-in-class KRAS G12D-targeted protein degrader — relevant given that KRAS G12D occurs in approximately 40% of PDAC patients — showed a 24% response rate and a median OS of 10.3 months among 21 patients with mPDAC receiving the 600-mg dose as second- or third-line therapy, with a manageable safety profile and low treatment discontinuation rates. Early-phase combinations, including HRS-4642 (KRAS G12D inhibitor) paired with nimotuzumab (EGFR inhibitor), are also under active investigation. Collectively, these data reflect a field at an inflection point: while chemotherapy remains the backbone of first-line treatment, molecularly targeted strategies — particularly against KRAS — are emerging as viable options for defined patient subpopulations, with daraxonrasib representing the most clinically mature advance to date.

Daraxonrasib's Accelerated Path: A New Horizon for mPDAC

For patients battling metastatic pancreatic ductal adenocarcinoma (mPDAC), a diagnosis often comes with a grim prognosis and limited therapeutic avenues. The recent news regarding daraxonrasib, an oral RAS(ON) multiselective inhibitor, offers a significant beacon of hope. The European Medicines Agency's decision to initiate a phased review, accelerating its assessment under the Cancer Medicines Pathfinder project, highlights the profound unmet medical need and the compelling clinical data supporting this novel therapy.

Research indicates that daraxonrasib has achieved an unprecedented doubling of overall survival compared to chemotherapy in previously treated mPDAC patients, a remarkable feat in an indication where therapeutic gains are typically incremental. This robust efficacy, coupled with a manageable safety profile where treatment discontinuation rates were significantly lower than chemotherapy, positions daraxonrasib as a potential new standard of care.

Beyond pancreatic cancer, the strategic implications of daraxonrasib's pan-RAS inhibition are far-reaching. Preclinical studies have demonstrated its activity in other RAS-mutant cancers, such as neuroblastoma and cholangiocarcinoma, suggesting a broader utility for this targeted therapy. However, the journey is not without its challenges:

• Adverse Event Management: While generally better tolerated than chemotherapy, a substantial proportion of patients experienced grade 3 or higher adverse events, underscoring the need for vigilant patient monitoring and proactive management strategies.

• Resistance Mechanisms: Existing evidence points to the potential for intrinsic and acquired resistance, often driven by RAS signaling overactivation. This suggests that while daraxonrasib is highly effective as a monotherapy, future strategies may involve combination approaches to sustain long-term benefits.

Indeed, preclinical work has already explored combination therapies, showing that co-targeting RAS with EGFR and STAT3 inhibitors can lead to complete tumor regression and prevent resistance. This forward-looking perspective suggests that daraxonrasib could serve as a foundational therapy, paving the way for innovative combination regimens that further enhance patient outcomes across a spectrum of RAS-driven malignancies. This accelerated review is not just about a single drug; it represents a pivotal moment in the fight against some of the most challenging cancers.